Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

According to the companies, the trial named VERITAC-2 reached the primary endpoint